CANCER CHEMOTHERAPY ASSOCIATED NAUSEA AND VOMITING THERAPEUTICS MARKET ANALYSIS

Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type (Acute CINV, Delayed CINV, Anticipatory nausea and emesis and Breakthrough CINV/Refractory CINV), By Drug Class (Dopamine Receptor Antagonists (Metoclopramide, Chlorpromazine, Prochlorperazine, Haloperidol, Droperidol and Others), Serotonin (5-HT3) receptor Antagonists (Ondansetron, Granisetron, Palonosetron, Dolasetron and others), Substance P/NK-1 Antagonists (Aprepitant, Fosaprepitant, Netupitant, and Others), Corticosteroids (Dexamethasone and Methylprednisolone) and others), By Route of Administration (Oral, Parenteral and Transdermal Patch), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023
Code : CMI5823
Pages :266
Formats :
Excel and PDF
Industry : Pharmaceutical

Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics MarketSize and Trends

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market is estimated to be valued at US$ 3,071.1 Million in 2023, exhibiting a CAGR of 5.7% during the forecast period (2023-2030).

Figure 1. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Share (%), By Type, 2023

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market– Drivers

Rising cancer prevalence will increase the number of chemotherapies is expected to drive the global cancer chemotherapy associated nausea and vomiting therapeutics market growth over the forecast period. For instance, according to the data provided by the World Health Organization, in February 2022, the most common types of cancer were breast cancer accounting for 2.26 million cases and lung cancer accounting for 2.21 million cases in the year 2020, globally. Moreover, according to the data provided by the World Health Organization in February 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.

Figure 2. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Share (US$ Million), By Region, 2023